Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | L1₹1Accepted-AOC 1ST AND 2ND FLOOR NXT TOWER 2 EMBASSY MANYATA BUSINESS PARK NAGAVARA VILLAGE KASABA HOBLI BANGALORE KARNATAKA INDIA 560045 | BANGALORE | BANGALORE | KARNATAKA | 560045 | ₹1 | L1 | Accepted-AOC L1 |
| 2 | L1₹1Accepted-AOC 4TH FLOOR B WING ZYDUS CORPORATE PARK S G HIGHWAY NEAR VAISHNODEVI CIRCLE AHMEDABAD GUJARAT 382481 | AHMADABAD | GUJARAT | 382481 | ₹1 | L1 | Accepted-AOC L1 |
| 3 | Ln₹1Rejected-Finance | ₹1 | Ln | Rejected-Finance REJECTED |
| 4 | Ln₹1Rejected-Finance CORPORATE HOUSE NEAR SOLA BRIDGE S G HIGHWAY THALTEJ AHMEDABAD GUJARAT 380054 | AHMADABAD | GUJARAT | 380054 | ₹1 | Ln | Rejected-Finance REJECTED |
| 5 | Ln₹1Rejected-Finance 6TH FLOOR BUILDING NO 8 TOWER C DLF CYBER CITY PHASE II MOTI NAGAR GURGAON WEST DELHI DELHI 122002 | GURUGRAM | HARYANA | 122002 | ₹1 | Ln | Rejected-Finance REJECTED |
| Sl No | Description | Qty | Unit | Novonordisk India Private Limited L4 | Intas Pharmaceuticals Ltd. L3 | Grifols India Healthcare Private Limited L1 | TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED L2 | Zydus Lifesciences Limited L5 |
|---|---|---|---|---|---|---|---|---|
| 1.00 | Plasma Derived Factor VIII (500 IU./ 250 IU.) /Vial | 2,00,00,000 | Per IU | - | 16.5 ₹16.50 | 9 ₹9 | 10.75 ₹10.75 | - |
| 2.00 | Recombinant anti Hemophilic Factor VIII with Extended Half Life ( EHL) (Pegylated/Glyco-pegylated) 1000 IU / vial | 1,00,00,000 | Per IU | 13.98 ₹13.98 | - | - | - | - |
| 3.00 | Recombinant anti Hemophilic Factor VIII with Extended Half Life ( EHL) (Pegylated/Glyco-pegylated) 500 IU / vial | 25,00,000 | Per IU | 13.98 ₹13.98 | - | - | - | - |
| 4.00 | Recombinant Anti Hemophilic Factor VIII 1000 IU./Vial | 1,00,00,000 | Vial | - | - | - | - | - |
| 5.00 | Recombinant Anti Hemophilic Factor VIII 250 IU./Vial | 25,00,000 | Vial | - | - | - | - | - |
| 6.00 | Trastuzumab Emtansine Inj. 100mg per Vial/PFS | 1,000 | PFS / Vial | - | - | - | - | 24,177.83 ₹24,177.83 |
| 100.00Important Note: 1. All prospective bidders are requested to quote the rate in BOQ as per Accounting Unit & item specification as mentioned in the Table-A. Wrong Quoting of the rate in BOQ will be dealt with as per penal provisions of the T&C of the Tender. 2. Quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 3. The prospective Bidders of the said Tender are requested to make a declaration in Affidavit under Annexure VI(b) in case of sole manufacturer/importer (i.e. proprietary in nature). 4. If the Item(s) under sole manufacturer / importer is (are) Proprietary in nature, quarterly intimation is solicited from the approved Bidders positively regarding the status of their Item(s) Proprietary in nature, otherwise their Item(s) will be blocked in the SMIS. 5. In case of Tie Bid, decision will be taken by the TIA as per G.O. No. 2320-F(Y), dated 07.06.2022 issued from Finance Department Audit Branch (Group T). | ||||||||
Tender Value
Refer Docs
EMD Value
₹10 L
Closing Date
30 Oct 2025, 11:00 amClosed
THE DY. DIRECTOR OF HEALTH SERVICES (E AND S)
Central Medical Stores 141, A J C Bose Road, Kolkata 700014
RE E-TENDER (2ND CALL) FOR PROCUREMENT OF SOME DRUG ITEMS UNDER TABLE-A, FOR TWO YEARS FROM THE DATE OF AOC.
2025_HFW_905362_1
WBHF/ CMS/ HST/4T-118-2025/ SDI-RT(357)/2025/361
Open Tender
Medicines
730 days
KOLKATA
Please refer Tender documents.
3 documents required · 3 mandatory
₹10 L
Yes
8 May 2026
18 Sept 2025
30 Oct 2025
18 Sept 2025
30 Oct 2025
25 Sept 2025
Plasma Derived Factor VIII (500 IU./ 250 IU.) /Vial
Recombinant anti Hemophilic Factor VIII with Extended Half Life ( EHL) (Pegylated/Glyco-pegylated) 1000 IU / vial
Recombinant anti Hemophilic Factor VIII with Extended Half Life ( EHL) (Pegylated/Glyco-pegylated) 500 IU / vial
Recombinant Anti Hemophilic Factor VIII 1000 IU./Vial
Recombinant Anti Hemophilic Factor VIII 250 IU./Vial
Trastuzumab Emtansine Inj. 100mg per Vial/PFS
Important Note: 1. All prospective bidders are requested to quote the rate in BOQ as per Accounting Unit & item specification as mentioned in the Table-A. Wrong Quoting of the rate in BOQ will be dealt with as per penal provisions of the T&C of the Tender. 2. Quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 3. The prospective Bidders of the said Tender are requested to make a declaration in Affidavit under Annexure VI(b) in case of sole manufacturer/importer (i.e. proprietary in nature). 4. If the Item(s) under sole manufacturer / importer is (are) Proprietary in nature, quarterly intimation is solicited from the approved Bidders positively regarding the status of their Item(s) Proprietary in nature, otherwise their Item(s) will be blocked in the SMIS. 5. In case of Tie Bid, decision will be taken by the TIA as per G.O. No. 2320-F(Y), dated 07.06.2022 issued from Finance Department Audit Branch (Group T).
TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED (BID ID -7097543)
Intas Pharmaceuticals Ltd. (BID ID -7107710)
Novonordisk India Private Limited (BID ID -7063048)
Zydus Lifesciences Limited (BID ID -7216042)
Grifols India Healthcare Private Limited
Zydus Lifesciences Limited
stage.html
html • 0.05 MB
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
fin_eval.pdf
aoc.pdf
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Tendernotice_1.pdf
PDF • 1.72 MB
BOQ_2052973.xls
BOQ • 0.26 MB
Technical_Data_Sheet_361.xls
Tender Documents • 2.71 MB
Download all tender documents and submit your bid